On the contrary, NRF2 silencing was unable to repress GLO2 upregulation in androgen-responsive prostate cancerous cells, while androgen receptor silencing abolished GLO2 upregulation but not that of NRF2 [43]. The gene discussed is HAGH; the disease is medical procedure.